RT Journal Article
SR Electronic
T1 Novel drugs against tuberculosis: a clinician's perspective
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 1119
OP 1131
DO 10.1183/09031936.00162314
VO 45
IS 4
A1 Ioana Diana Olaru
A1 Florian von Groote-Bidlingmaier
A1 Jan Heyckendorf
A1 Wing Wai Yew
A1 Christoph Lange
A1 Kwok Chiu Chang
YR 2015
UL http://erj.ersjournals.com/content/45/4/1119.abstract
AB The United Nations Millennium Development Goal of reversing the global spread of tuberculosis by 2015 has been offset by the rampant re-emergence of drug-resistant tuberculosis, in particular fluoroquinolone-resistant multidrug-resistant and extensively drug-resistant tuberculosis. After decades of quiescence in the development of antituberculosis medications, bedaquiline and delamanid have been conditionally approved for the treatment of drug-resistant tuberculosis, while several other novel compounds (AZD5847, PA-824, SQ109 and sutezolid) have been evaluated in phase II clinical trials. Before novel drugs can find their place in the battle against drug-resistant tuberculosis, linezolid has been compassionately used with success in the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis. This review largely discusses six novel drugs that have been evaluated in phase II and III clinical trials, with focus on the clinical evidence for efficacy and safety, potential drug interactions, and prospect for using multiple novel drugs in new regimens.A review of the efficacy, safety, and potential of new drugs to improve TB therapy from the perspective of clinicians http://ow.ly/Das5l